Given the essential function of POLR2A, further suppression by the RNA polymerase inhibitor alpha‐amanitin could inhibit the survival and the proliferation of colorectal cancer cells with hemizygous TP53 and POLR2A deletion, suggesting a novel strategy for molecular targeted therapy (Liu et al., 2015). The gene discussed is TP53; the disease is colorectal cancer.